Health Professional Radio - Podcast
Esperion is developing a therapy for patients who have high LDL-C
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:11:33
- Mas informaciones
Informações:
Sinopsis
CEO of Esperion, Tim Mayleben, speaks to the need for more therapies / options in the cholesterol-lowering space. Esperion is developing a therapy (with an FDA approval date marked for February 2020) that will provide another treatment option for patients who have high LDL-C (bad cholesterol levels).
